Holberg EEG’s lead product, autoSCORE, is capable of automatic and comprehensive clinical EEG interpretation. Credit: Natus Medical Incorporated / PRNewswire.

US-based Natus Medical has acquired the remaining shares of Holberg EEG, securing full ownership of the company, to boost neurological diagnostics.

This acquisition aims to integrate Holberg EEG’s advanced AI model with Natus’ existing neurodiagnostic tools while the companies’ combined expertise aims to foster further AI-powered advancements in brain health.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Holberg EEG AI model can interpret electroencephalogram (EEG) data with precision comparable to that of medical experts.

By integrating Holberg EEG with Natus’s EEG systems, healthcare providers worldwide are able to improve diagnostic workflows and patient outcomes. 

Natus CEO Chris Landon said: “Bringing Holberg EEG into the Natus family is an exciting and strategic milestone for our company and the field of neurodiagnostics. 

“This acquisition allows us to accelerate the adoption of cutting-edge AI technology that empowers healthcare providers and technologists with faster, more accurate EEG interpretation – improving patient outcomes worldwide.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“We are proud to unite our deep heritage in neuro care with Holberg’s groundbreaking innovation, creating a powerful force for advancing brain health for decades.”

Established in 2009, as a spin-off from Haukeland University Hospital in Norway, Holberg EEG specialises in AI-driven interpretation technology.

Its lead product, autoSCORE, trained on a vast dataset of more than 30,000 EEG recordings, was launched in the US in August 2024. The solution is available exclusively with Natus’ NeuroWorks software. 

It has received both US Food and Drug Administration (FDA) 510(k) clearance and CE marking for its applications in routine EEG, long-term monitoring, and ambulatory EEG studies. 

Last year, Natus Medical submitted a 510(k) premarket notification to the US FDA seeking clearance for its point-of-care EEG device.

This decision-support tool is engineered to rapidly identify non-convulsive seizures and status epilepticus in acute care settings.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact